Address: Minervum 7061, 4817 ZK, Breda,Netherlands
Tel: 076-5732500
Web: http://www.amgen.nl/dutch/index.html
Sinds 1997 levert Amgen vanuit Breda haar producten door heel Europa en aan een groeiend aantal landen in andere delen van de wereld. We verpakken medicijnen landenspecifiek, slaan ze tijdelijk op en verschepen uiteindelijk naar meer dan 50 landen.
Voor Amgen Europe B.V. geldt: “Elke patiënt, telkens weer”. Hiermee bedoelen we dat we ernaar streven om onze producten altijd beschikbaar te hebben op de juiste plaats en op de juiste tijd voor de behandeling van de patiënt. Vanuit Breda distribueren we zowel geregistreerde producten als producten die gebruikt worden in klinisch onderzoek. Breda is ook de vestigingsplaats van twee onderdelen van de Global Supply Chain organisatie verantwoordelijk voor Europa, Afrika en Australië/Nieuw-Zeeland. Daarnaast is Amgen Breda het internationale centrum buiten de Verenigde Staten voor enkele andere functies, zoals Quality & Regulatory Compliance, Information Systems en Financial Shared Services.
Circa 500 gemotiveerde mensen werken samen in hun streven naar perfectie in hun werkzaamheden, met als uiteindelijke doel het verbeteren van mensenlevens.
Amgen has marketed various key breakthrough products including Aranesp, Neulasta, Neupogen, Mimpara en Nplate all of which have made a vital contribution to patients’ welfare. Amgen’s future aims will also remain centred on finding innovative solutions for patients. This is why Amgen continues to develop new products for syndromes where treatment options are insufficient.
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the Dutch ambition to be a frontrunner in new healthcare challenges also comprises an…
Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to improve the lives of rare disease patients and their families. Karel Fol, the country manager…
Paul Korte, General Manager for Janssen in the Netherlands, highlights the strategic move and leadership position taken up by Janssen in the oncology field, and calls on Dutch healthcare stakeholders…
In an exclusive interview, the Vice President of Philips Research explains the key to continuous evolution, improving healthcare stakeholder relations, and fostering “Open Innovation.” You have been Vice President of…
Healthcare is moving towards an increased level of personalization and active participation of the patient in the decision-making process. Roland van Esch, General Manager of Zimmer Biomet Netherlands, shares his…
See our Cookie Privacy Policy Here